FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3206061808> ?p ?o ?g. }

• W3206061808 abstract "Background: The European Friedreich’s Ataxia Consortium for Translational Studies (EFACTS) investigates the natural history of Friedreich’s ataxia (FRDA) in a prospective multinational registry study. We aimed to assess progression and metric characteristics of clinical rating scales based on longitudinal 4-year data. Methods: Patients with genetically confirmed FRDA from 11 European sites were seen on a yearly basis at five visits. Our primary endpoints were the clinical Scale for the Assessment and Rating of Ataxia (SARA) and the functional activities of daily living (ADL) scale. Secondary endpoints were the Spinocerebellar Ataxia Functional Index (SCAFI), the Inventory of Non-Ataxia Signs (INAS), and the quality of life measure EQ-5D-3L index. Annual disease progression was analysed with linear mixed effect models and additional regression statistics for detailed subgroup characterization. . Findings: 602 FRDA patients were seen between 29-Oct-2010 and 05-Mar-2018. 552 patients (92%) contributed data with at least one follow-up visit. Annual progression rate for SARA was 0·82 points (SE 0·05) in the overall cohort, and higher in ambulatory (1·12 [0·07]) compared to non-ambulatory (0·50 [0·07]) patients. Subitem analyses revealed high rates of progression for the lower limb components in ambulatory patients. ADL worsened with 0·93 (0·05) points per year, with the subitem falls showing strongest effects over time. Annual worsening of INAS was 0·09 (0·02) points, for SCAFI -0·05 (0·01) and for EQ-5D-3L -0·02 (0·003). For a two-year parallel-group clinical trial, about 118 (59 per group) ambulatory patients are required to detect a 50% reduction in SARA progression at 80% power. Less patients are needed using ADL as a functional outcome in a similar design and including only early-onset ambulatory individuals. Interpretation: EFACTS 4-year longitudinal data analysis provides reliable outcome measures and tailored sample size calculation for upcoming clinical trial designs in FRDA.Trial Registration: This study is registered at https://clinicaltrials.gov (NCT02069509)Funding Statement: FP7 Grant from the European Commission (HEALTH-F2-2010- 242193), Voyager Therapeutics and Euro-Ataxia.Declaration of Interests: The authors declare no potential conflicts of interests.Ethics Approval Statement: All patients and/or their authorized surrogates provided written informed consent upon enrolment into EFACTS. This study was approved by the local ethics committees of each participating centre." @default.
• W3206061808 created "2021-10-25" @default.
• W3206061808 creator A5000608187 @default.
• W3206061808 creator A5002298880 @default.
• W3206061808 creator A5011890829 @default.
• W3206061808 creator A5012241488 @default.
• W3206061808 creator A5013428782 @default.
• W3206061808 creator A5014302098 @default.
• W3206061808 creator A5023493760 @default.
• W3206061808 creator A5024040961 @default.
• W3206061808 creator A5026565602 @default.
• W3206061808 creator A5027293126 @default.
• W3206061808 creator A5036929784 @default.
• W3206061808 creator A5037328125 @default.
• W3206061808 creator A5039729410 @default.
• W3206061808 creator A5047376869 @default.
• W3206061808 creator A5047819566 @default.
• W3206061808 creator A5057192241 @default.
• W3206061808 creator A5067483880 @default.
• W3206061808 creator A5073735143 @default.
• W3206061808 creator A5078587237 @default.
• W3206061808 creator A5080418392 @default.
• W3206061808 creator A5086356522 @default.
• W3206061808 date "2020-01-01" @default.
• W3206061808 modified "2023-10-17" @default.
• W3206061808 title "Progression Characteristics in Friedreich's Ataxia: A 4-Year Observational Study" @default.
• W3206061808 doi "https://doi.org/10.2139/ssrn.3723615" @default.
• W3206061808 hasPublicationYear "2020" @default.
• W3206061808 type Work @default.
• W3206061808 sameAs 3206061808 @default.
• W3206061808 citedByCount "0" @default.
• W3206061808 crossrefType "journal-article" @default.
• W3206061808 hasAuthorship W3206061808A5000608187 @default.
• W3206061808 hasAuthorship W3206061808A5002298880 @default.
• W3206061808 hasAuthorship W3206061808A5011890829 @default.
• W3206061808 hasAuthorship W3206061808A5012241488 @default.
• W3206061808 hasAuthorship W3206061808A5013428782 @default.
• W3206061808 hasAuthorship W3206061808A5014302098 @default.
• W3206061808 hasAuthorship W3206061808A5023493760 @default.
• W3206061808 hasAuthorship W3206061808A5024040961 @default.
• W3206061808 hasAuthorship W3206061808A5026565602 @default.
• W3206061808 hasAuthorship W3206061808A5027293126 @default.
• W3206061808 hasAuthorship W3206061808A5036929784 @default.
• W3206061808 hasAuthorship W3206061808A5037328125 @default.
• W3206061808 hasAuthorship W3206061808A5039729410 @default.
• W3206061808 hasAuthorship W3206061808A5047376869 @default.
• W3206061808 hasAuthorship W3206061808A5047819566 @default.
• W3206061808 hasAuthorship W3206061808A5057192241 @default.
• W3206061808 hasAuthorship W3206061808A5067483880 @default.
• W3206061808 hasAuthorship W3206061808A5073735143 @default.
• W3206061808 hasAuthorship W3206061808A5078587237 @default.
• W3206061808 hasAuthorship W3206061808A5080418392 @default.
• W3206061808 hasAuthorship W3206061808A5086356522 @default.
• W3206061808 hasConcept C118552586 @default.
• W3206061808 hasConcept C126322002 @default.
• W3206061808 hasConcept C159110408 @default.
• W3206061808 hasConcept C163276114 @default.
• W3206061808 hasConcept C1862650 @default.
• W3206061808 hasConcept C187212893 @default.
• W3206061808 hasConcept C201903717 @default.
• W3206061808 hasConcept C203092338 @default.
• W3206061808 hasConcept C23131810 @default.
• W3206061808 hasConcept C2778279407 @default.
• W3206061808 hasConcept C2779500118 @default.
• W3206061808 hasConcept C2779951463 @default.
• W3206061808 hasConcept C2780906641 @default.
• W3206061808 hasConcept C35785553 @default.
• W3206061808 hasConcept C535046627 @default.
• W3206061808 hasConcept C71924100 @default.
• W3206061808 hasConcept C72563966 @default.
• W3206061808 hasConceptScore W3206061808C118552586 @default.
• W3206061808 hasConceptScore W3206061808C126322002 @default.
• W3206061808 hasConceptScore W3206061808C159110408 @default.
• W3206061808 hasConceptScore W3206061808C163276114 @default.
• W3206061808 hasConceptScore W3206061808C1862650 @default.
• W3206061808 hasConceptScore W3206061808C187212893 @default.
• W3206061808 hasConceptScore W3206061808C201903717 @default.
• W3206061808 hasConceptScore W3206061808C203092338 @default.
• W3206061808 hasConceptScore W3206061808C23131810 @default.
• W3206061808 hasConceptScore W3206061808C2778279407 @default.
• W3206061808 hasConceptScore W3206061808C2779500118 @default.
• W3206061808 hasConceptScore W3206061808C2779951463 @default.
• W3206061808 hasConceptScore W3206061808C2780906641 @default.
• W3206061808 hasConceptScore W3206061808C35785553 @default.
• W3206061808 hasConceptScore W3206061808C535046627 @default.
• W3206061808 hasConceptScore W3206061808C71924100 @default.
• W3206061808 hasConceptScore W3206061808C72563966 @default.
• W3206061808 hasLocation W32060618081 @default.
• W3206061808 hasOpenAccess W3206061808 @default.
• W3206061808 hasPrimaryLocation W32060618081 @default.
• W3206061808 hasRelatedWork W10586329 @default.
• W3206061808 hasRelatedWork W11509916 @default.
• W3206061808 hasRelatedWork W1836420 @default.
• W3206061808 hasRelatedWork W18427999 @default.
• W3206061808 hasRelatedWork W18689917 @default.
• W3206061808 hasRelatedWork W2174129 @default.
• W3206061808 hasRelatedWork W3046699 @default.
• W3206061808 hasRelatedWork W6986156 @default.
• W3206061808 hasRelatedWork W8808446 @default.
• W3206061808 hasRelatedWork W9857653 @default.

• next